Insulatard (isophane insulin) / Novo Nordisk - LARVOL DELTA

Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (clinicaltrials.gov) - P4 | N=44 | Completed | Sponsor: Hospital Sultanah Aminah Johor Bahru

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety and efficacy of different basal insulin in type 2 diabetes mellitus with chronic kidney disease in Ramadan: prospective observational study. (PubMed, BMC Endocr Disord) - "This study revealed that Insulatard, Levemir, and Glargine demonstrated similar levels of safety and efficacy among those with diabetic kidney disease who observed fasting during Ramadan."

Journal • Observational data • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypoglycemia • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • MIR34A

Antidiabetic activity of Inonotus obliquus water extract in alloxan-induced diabetic mice. (PubMed, J Complement Integr Med) - "Natural Mongolian I. Obliquus water extracts have an antihyperglycemic effect and enhance islet cell function in alloxan-induced diabetic mice. It is a good candidate for a hypoglycemic functional food or medicine."

Journal • Preclinical • Diabetes • Metabolic Disorders

Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding. (PubMed, Int J Pharm) - "Drug disappearance was assessed for solution, suspension and in situ precipitating insulin products (Actrapid, Levemir, Tresiba, Mixtard 30, Insulatard, Lantus) using the flow-based cartridge. Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions."

Journal • Preclinical

Case Report: Long Standing Type 2 Diabetes with TOFI Phenotype Successfully Weaned Off One Hundred Units of Basal-Bolus Insulin Therapy With Glucagon-Like Peptide 1 Receptor Agonist Therapy (ENDO 2024) - "Since Sep 2017, he had been compliant on the same stable regimen of sc insulatard 20 units om and 20 units at 10 pm, sc actrapid 20 units t.i.d premeal, PO metformin 850 mg t.i.d and PO dapagliflozin 10 mg om...His cardiac medications included bisoprolol fumarate 5 mg om, losartan 25 mg om, spironolactone 25 mg om, aspirin 100 mg om and high intensity statin therapy.Since 2020, his HbA1c had measured 8% to 9% with FBGL at 6 mM to 11 mM...Basal insulatard was discontinued and he was switched from liraglutide to sc dulaglutide 1.5 mg once weekly...As he continued to experience occasional minor hypoglycemic episodes, actrapid insulin was discontinued.On his current therapy of sc dulaglutide 1.5 mg once weekly, PO empagliflozin 25 mg om, PO metformin 850 mg tid, and PO acarbose 50 mg t.i.d, his fasting CBG measured 6.7-7.7 mM, premeal CBG 6.4 to 10.1 mM, off all insulins and without further episodes hypoglycaemia. Patients with long standing "TOFI" type 2 diabetes..."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Diabetes • Hypoglycemia • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

DEES: Detemir Energy Expenditure Study (clinicaltrials.gov) - P4 | N=30 | Completed | Sponsor: University of Surrey | Unknown status ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS CHILDREN WITH DIABETES MELLIUS TYPE 1 USING DIFFERENT TYPES OF INSULIN PREPARATIONS. (PubMed, Georgian Med News) - "Group 1 included 20 children who used Insulin human (Insulatard), group 2 included 15 children using insulin Glargine, and group 3 included 14 children using insulin Detemir...Those using Insulin human (Insulatard) used Human insulin (rDNA, Actrapid) in addition...However, no such relationship between Glargine, body mass and height was recorded. It was a negative correlation between its dose Glargine with glycohemoglobin and also between glucose and cholesterol using Glargine."

Journal • Diabetes • Metabolic Disorders

"Lispro, aspart, actrapid (all with Ps are given in postprandial hyperglycaemia. Insulatard and the long acting lantus and determir- fasting hyperglycaemia. The premixes can be given in both. #diabetes #insulins @UgandaDiabetes @AmDiabetesAssn @DiabetesEd" (@NSengoobaa)

Diabetes • Metabolic Disorders

[VIRTUAL] SARS-CoV-2 Trigger in Severe Insulin Resistance With Acute Haemolytic Crisis in Diabetes and Glucose-6-phosphate Dehydrogenase Deficiency (ENDO 2021) - "As per hospital guidelines, the patient was treated with amoxicillin/clavulanate 625mg three times daily and doxycycline 100mg once daily...Later the patient was started on dexamethasone 6mg once daily (day 11) and on remdesivir 100mg once daily (day 15)...At this time, continuous insulin infusion was stopped and intermediate acting insulin (insulatard 36U twice daily; later increased to 48U twice daily) was started... This is a case demonstrating the possible role of SARS-CoV-2 in increased insulin resistance and severe haemolytic crisis on background of diabetes and G6PD deficiency. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20. For oral presentations, the abstracts are embargoed until the session begins."

Critical care • Diabetes • Fatigue • Gout • Hematological Disorders • Hypertension • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Septic Shock • Type 2 Diabetes Mellitus

Towards In Vitro In Vivo Correlation for Modified Release Subcutaneously Administered Insulins. (PubMed, Eur J Pharm Sci) - "A novel gel-based flow-through method with the incorporation of an injection step was used to assess selected commercial insulin formulations with different duration of action (Actrapid®, Mixtard® 30, Insulatard®, Lantus®). Predicted absorption profiles were constructed using the in vitro in vivo correlation and subsequently converted into simulated plasma profiles. The approach taken may be of wider utility in characterizing injectables for subcutaneous administration."

Journal • Preclinical